Patent ID: 8470796
Filing Date: 2013-06-25
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method for treating a cancer in a human subject, comprising administering to the subject a therapeutic combination comprising: (a) an agent that reduces IGFBP-2 and/or IGFBP-5 and (b) an oligonucleotide effective to reduce the effective amount of clusterin in the cancer cells, wherein the cancer is one for which reduction in the amount of IGFBP-2 and/or IGFBP-5 is of therapeutic benefit, wherein the oligonucleotide effective to reduce the amount of clusterin is an anti-clusterin antisense oligonucleotide that consists essentially of an oligonucleotide selected from the group consisting of Seq. ID. Nos.: 2 to 19, wherein the agent that inhibits IGFBP-2 and/or IGFBP-5 is an oligodeoxynucleotide and wherein substantially all of the oligodeoxynucleotide consists essentially of a sequence of bases that is complementary to a portion of a gene encoding human IGFBP-2 and substantial) all of the oligodeoxynucleotide is also complementary to a portion of a gene encoding human IGFBP-5, and wherein the oligodeoxynucleotide consists essentially of a sequence selected from among Seq. ID Nos 45-51.